Moderna is trading at $153.71 (+10.67%) as investors extend the sharp repricing after its August 19 Phase 3 melanoma-vaccine results with Merck showed reduced recurrence and distant spread in patients.
- Bank of America upgraded Moderna and raised its price target to $170, reinforcing investor optimism.
- The broader biotech rally is adding sector support, with XBI up 2.06%.